Standard

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. / van der Helm, Jannie; Geskus, Ronald; Sabin, Caroline et al.

In: Gastroenterology, Vol. 144, No. 4, 2013, p. 751-760.e2.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

van der Helm, J, Geskus, R, Sabin, C, Meyer, L, del Amo, J, Chene, G, Dorrucci, M, Muga, R, Porter, K, Prins, M & AUTHOR GROUP 2013, 'Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997', Gastroenterology, vol. 144, no. 4, pp. 751-760.e2. https://doi.org/10.1053/j.gastro.2012.12.026

APA

van der Helm, J., Geskus, R., Sabin, C., Meyer, L., del Amo, J., Chene, G., Dorrucci, M., Muga, R., Porter, K., Prins, M., & AUTHOR GROUP (2013). Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology, 144(4), 751-760.e2. https://doi.org/10.1053/j.gastro.2012.12.026

Vancouver

Author

van der Helm, Jannie ; Geskus, Ronald ; Sabin, Caroline et al. / Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. In: Gastroenterology. 2013 ; Vol. 144, No. 4. pp. 751-760.e2.

BibTeX

@article{19802f25512a490983b6b4c665c6f9ad,
title = "Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997",
abstract = "Individuals with human immunodeficiency virus (HIV) infection frequently also are infected with hepatitis C virus (HCV) (co-infection), but little is known about its effects on the progression of HIV-associated disease. We aimed to determine the effects of co-infection on mortality from HIV and/or acquired immune deficiency syndrome (AIDS), and hepatitis or liver disease, adjusting for the duration of HIV infection. We analyzed data from the 16 cohorts of the Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) collaboration, which included information on HCV infection and cause of death. A competing-risks proportional subdistribution hazards model was used to evaluate the effect of HCV infection on the following causes of death: HIV- and/or AIDS-related, hepatitis- or liver-related, natural, and non-natural. Of 9164 individuals with HIV infection and a known date of seroconversion, 2015 (22.0%) also were infected with HCV. Of 718 deaths, 395 (55.0%) were caused by HIV infection and/or AIDS, and 39 (5.4%) were caused by hepatitis or liver-related disease. Among individuals infected with only HIV or with co-infection, the mortality from HIV infection and/or AIDS-related causes and hepatitis or liver disease decreased significantly after 1997, when combination antiretroviral therapy became widely available. However, after 1997, HIV and/or AIDS-related mortality was higher among co-infected individuals than those with only HIV infection in each risk group: injection drug use (adjusted hazard ratio [aHR], 2.43; 95% confidence interval [CI], 1.14-5.20), sex between men and women or hemophilia (aHR, 3.43; 95% CI, 1.70-6.93), and sex between men (aHR, 3.11; 95% CI, 1.49-6.48). Compared with individuals infected with only HIV, co-infected individuals had a higher risk of death from hepatitis or liver disease. Based on analysis of data from the CASCADE collaboration, since 1997, when combination antiretroviral therapy became widely available, individuals co-infected with HIV and HCV have had a higher risk of death from HIV and/or AIDS, and from hepatitis or liver disease, than patients infected with only HIV. It is necessary to evaluate the effects of HCV therapy on HIV progression",
author = "{van der Helm}, Jannie and Ronald Geskus and Caroline Sabin and Laurence Meyer and {del Amo}, Julia and Genevieve Chene and Maria Dorrucci and Roberto Muga and Kholoud Porter and Maria Prins and {AUTHOR GROUP} and Bucher, {Heiner C.} and Osamah Hamouda and Deenan Pillay and Magda Rosinska and Giota Touloumi and Ashley Olson and Kate Coughlin and Sarah Walker and Abdel Babiker and {de Luca}, Andrea and Martin Fisher and Robert Zangerle and Tony Kelleher and David Cooper and Pat Grey and Robert Finlayson and Mark Bloch and Tim Ramacciotti and Linda Gelgor and Don Smith and John Gill and Irja Lutsar and Francois Dabis and Rodolphe Thiebaut and Bernard Masquelier and Dominique Costagliola and Marguerite Guiguet and Philippe Vanhems and Jade Ghosn and Faroudy Boufassa and Claudia Kuecherer and Barbara Bartmeyer and Vasilios Paparizos and Panagiotis Gargalianos-Kakolyris and Marios Lazanas and Nikos Pantazis and Olga Katsarou and {D'Arminio Monforte}, Antonella and Hanneke Schuitemaker and Mette Sannes",
year = "2013",
doi = "10.1053/j.gastro.2012.12.026",
language = "English",
volume = "144",
pages = "751--760.e2",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997

AU - van der Helm, Jannie

AU - Geskus, Ronald

AU - Sabin, Caroline

AU - Meyer, Laurence

AU - del Amo, Julia

AU - Chene, Genevieve

AU - Dorrucci, Maria

AU - Muga, Roberto

AU - Porter, Kholoud

AU - Prins, Maria

AU - AUTHOR GROUP

AU - Bucher, Heiner C.

AU - Hamouda, Osamah

AU - Pillay, Deenan

AU - Rosinska, Magda

AU - Touloumi, Giota

AU - Olson, Ashley

AU - Coughlin, Kate

AU - Walker, Sarah

AU - Babiker, Abdel

AU - de Luca, Andrea

AU - Fisher, Martin

AU - Zangerle, Robert

AU - Kelleher, Tony

AU - Cooper, David

AU - Grey, Pat

AU - Finlayson, Robert

AU - Bloch, Mark

AU - Ramacciotti, Tim

AU - Gelgor, Linda

AU - Smith, Don

AU - Gill, John

AU - Lutsar, Irja

AU - Dabis, Francois

AU - Thiebaut, Rodolphe

AU - Masquelier, Bernard

AU - Costagliola, Dominique

AU - Guiguet, Marguerite

AU - Vanhems, Philippe

AU - Ghosn, Jade

AU - Boufassa, Faroudy

AU - Kuecherer, Claudia

AU - Bartmeyer, Barbara

AU - Paparizos, Vasilios

AU - Gargalianos-Kakolyris, Panagiotis

AU - Lazanas, Marios

AU - Pantazis, Nikos

AU - Katsarou, Olga

AU - D'Arminio Monforte, Antonella

AU - Schuitemaker, Hanneke

AU - Sannes, Mette

PY - 2013

Y1 - 2013

N2 - Individuals with human immunodeficiency virus (HIV) infection frequently also are infected with hepatitis C virus (HCV) (co-infection), but little is known about its effects on the progression of HIV-associated disease. We aimed to determine the effects of co-infection on mortality from HIV and/or acquired immune deficiency syndrome (AIDS), and hepatitis or liver disease, adjusting for the duration of HIV infection. We analyzed data from the 16 cohorts of the Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) collaboration, which included information on HCV infection and cause of death. A competing-risks proportional subdistribution hazards model was used to evaluate the effect of HCV infection on the following causes of death: HIV- and/or AIDS-related, hepatitis- or liver-related, natural, and non-natural. Of 9164 individuals with HIV infection and a known date of seroconversion, 2015 (22.0%) also were infected with HCV. Of 718 deaths, 395 (55.0%) were caused by HIV infection and/or AIDS, and 39 (5.4%) were caused by hepatitis or liver-related disease. Among individuals infected with only HIV or with co-infection, the mortality from HIV infection and/or AIDS-related causes and hepatitis or liver disease decreased significantly after 1997, when combination antiretroviral therapy became widely available. However, after 1997, HIV and/or AIDS-related mortality was higher among co-infected individuals than those with only HIV infection in each risk group: injection drug use (adjusted hazard ratio [aHR], 2.43; 95% confidence interval [CI], 1.14-5.20), sex between men and women or hemophilia (aHR, 3.43; 95% CI, 1.70-6.93), and sex between men (aHR, 3.11; 95% CI, 1.49-6.48). Compared with individuals infected with only HIV, co-infected individuals had a higher risk of death from hepatitis or liver disease. Based on analysis of data from the CASCADE collaboration, since 1997, when combination antiretroviral therapy became widely available, individuals co-infected with HIV and HCV have had a higher risk of death from HIV and/or AIDS, and from hepatitis or liver disease, than patients infected with only HIV. It is necessary to evaluate the effects of HCV therapy on HIV progression

AB - Individuals with human immunodeficiency virus (HIV) infection frequently also are infected with hepatitis C virus (HCV) (co-infection), but little is known about its effects on the progression of HIV-associated disease. We aimed to determine the effects of co-infection on mortality from HIV and/or acquired immune deficiency syndrome (AIDS), and hepatitis or liver disease, adjusting for the duration of HIV infection. We analyzed data from the 16 cohorts of the Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) collaboration, which included information on HCV infection and cause of death. A competing-risks proportional subdistribution hazards model was used to evaluate the effect of HCV infection on the following causes of death: HIV- and/or AIDS-related, hepatitis- or liver-related, natural, and non-natural. Of 9164 individuals with HIV infection and a known date of seroconversion, 2015 (22.0%) also were infected with HCV. Of 718 deaths, 395 (55.0%) were caused by HIV infection and/or AIDS, and 39 (5.4%) were caused by hepatitis or liver-related disease. Among individuals infected with only HIV or with co-infection, the mortality from HIV infection and/or AIDS-related causes and hepatitis or liver disease decreased significantly after 1997, when combination antiretroviral therapy became widely available. However, after 1997, HIV and/or AIDS-related mortality was higher among co-infected individuals than those with only HIV infection in each risk group: injection drug use (adjusted hazard ratio [aHR], 2.43; 95% confidence interval [CI], 1.14-5.20), sex between men and women or hemophilia (aHR, 3.43; 95% CI, 1.70-6.93), and sex between men (aHR, 3.11; 95% CI, 1.49-6.48). Compared with individuals infected with only HIV, co-infected individuals had a higher risk of death from hepatitis or liver disease. Based on analysis of data from the CASCADE collaboration, since 1997, when combination antiretroviral therapy became widely available, individuals co-infected with HIV and HCV have had a higher risk of death from HIV and/or AIDS, and from hepatitis or liver disease, than patients infected with only HIV. It is necessary to evaluate the effects of HCV therapy on HIV progression

U2 - 10.1053/j.gastro.2012.12.026

DO - 10.1053/j.gastro.2012.12.026

M3 - Article

C2 - 23266560

VL - 144

SP - 751-760.e2

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -

ID: 1816785